fingolimod hydrochloride has been researched along with Sarcoma, Kaposi in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barkley, A; Silber, E; Tully, T | 1 |
| Brew, B; Walker, S | 1 |
2 other study(ies) available for fingolimod hydrochloride and Sarcoma, Kaposi
| Article | Year |
|---|---|
Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leg; Male; Multiple Sclerosis; Propylene Glycols; Recurrence; Remission, Spontaneous; Sarcoma, Kaposi; Sphingosine; Treatment Outcome | 2015 |
Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Sarcoma, Kaposi | 2016 |